- The next generation of Argá Medtech non-thermal cardiac ablation system shows promise for improving the accuracy, speed and flexibility of atrial fibrillation treatment
- Preliminary Feasibility Study Results Demonstrate the Company’s Coherent Sine-Burst Electroporation (CSE) Pulsed-Field Ablation Platform to Titration Lesion Depth Using Sinusoidal Waveforms
LAUSANNE, Switzerland and SAN DIEGO, April 27, 2022 (GLOBE NEWSWIRE) — Arga Medtecha company developing Coherent Sinusoidal Electroporation (CSE), a next-generation non-thermal cardiac ablation system for the treatment of cardiac arrhythmias, announced a poster presentation on preliminary results of its innovative technology at the 2022 Annual Meeting of Heart Rhythm Society (HRS), from April 29 to May 1 in San Francisco. The company’s CSE pulsed-field ablation (PFA) offers unparalleled flexibility in the treatment of atrial fibrillation (AF) with its proprietary CSE generator and multi-configurable catheter.
“AF affects 37.5 million people worldwide1, dramatically increasing their risk of stroke or heart attack and dramatically decreasing their quality of life,” said David Neale, CEO and co-founder of Argá Medtech. “Although the field of cardiac ablation has made major advances in the treatment of AF, outcomes have improved only marginally over the past 15 years and costs have increased. It is imperative to develop new tools that improve success rates while reducing procedural costs.
Argá Medtech’s unique CSE PFA platform offers several advantages over other PFA technologies, which are primarily powered by a square wave energy source. Argá’s new CSE system allows physicians to select all bipolar, all unipolar, or combinations of bipolar and unipolar energy delivery modes to titrate the lesion based on patient needs.
Argá Medtech’s catheter also offers unparalleled flexibility in its ability to perform any type of lesion needed to treat the patient’s AF, eliminating the need for additional ablation catheters. Its design allows the catheter to take different shapes allowing the creation of circular, linear or focal lesions. These benefits offer the potential to improve the accuracy, speed, safety and efficiency of cardiac ablation procedures while reducing procedural costs.
“Argá Medtech offers physicians an unparalleled ability to perform much more flexible and elegant ablation procedures, likely improving outcomes and reducing the need for repeat surgeries and reducing costs for hospitals and the healthcare system,” said Neale. . “We are very optimistic about the promise of our technology and expect to launch our first-in-human trial in 2022.”
HRS presentation reports the results of an animal feasibility study on the use of a multiprogrammable CSE waveform to obtain a titratable range of lesion depths that address tissue thickness variability in the atrium and the ventricle.
Multi-programmable coherent sinusoidal electroporation waveform for atrial and ventricular catheter ablation
Date: Friday, April 29, 2022
Weather: 1:30 p.m. – 1:45 p.m. PT
Location: Podium Abstract Pavilion 11
Authors: Micah Lee BS, Ricardo Roman BS, Ale Lopez BS, Mark Zurcher MS, Deborrah Hunt BS, Randy Werneth MS, Kurt S Hoffmayer MD.
About Arga Medtech
Argá Medtech SA (Argá) is a privately held, Switzerland-based medical device company founded by a seasoned team of medical device industry leaders. Argá is developing an innovative cardiac ablation system based on non-thermal energy for the treatment of cardiac arrhythmias. With the use of pulsed electric fields to create irreversible electroporation of cardiomyocytes, Argá is developing a safer, faster, cheaper and more effective cardiac ablation treatment to benefit millions of people with cardiac arrhythmias and fibrillation auricular. To learn more, visit https://argamedtech.com.
1Lippi G, Sanchis-Gomar F, Cervellin G. Global epidemiology of atrial fibrillation: a growing epidemic and a public health challenge. Int J Stroke. 2021 Feb;16(2):217-221. doi: 10.1177/1747493019897870. Epub 19 Jan 2020. Erratum in: Int J Stroke. 2020 Jan 28;1747493020905964. PMID: 31955707.
Media Contact: Erich Sandoval Lazar FINN Partners email@example.com